Clinical trials: Shingles
Herpes Zoster, Shingles
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fed conditions.
- Conditions
- Herpes Zoster, Shingles, Genital Herpes
- Trial name
- NCT01132716
- Testing
- Valacyclovir Hydrochloride
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Herpes Zoster, Shingles
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fasting conditions.
- Conditions
- Herpes Zoster, Shingles, Genital Herpes
- Trial name
- NCT01132729
- Testing
- Valacyclovir Hydrochloride
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Shingles, Herpes Zoster
A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
This is a multicenter, randomized, double-blind, parallel-group, active controlled comparative study of the safety and efficacy of 2 dosing regimens of FV-100 versus valacyclovir administered for 7 days in subjects with…
- Conditions
- Shingles, Herpes Zoster, Postherpetic Neuralgia
- Trial name
- NCT02412917
- Testing
- FV-100, valacyclovir
- Where
- United States
- Volunteers
- 237 people
- Sponsor
- ContraVir Pharmaceuticals, Inc.
Shingles
Optimal Timing of Zoster Vaccine After Zoster Illness
The purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patients aged over 50 with history of zoster within 5 years.
- Trial name
- NCT02704572
- Testing
- Zostavax
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Shingles
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.
- Trial name
- NCT00534248
- Testing
- Zoster Vaccine, Live (Zostavax™)
- Volunteers
- 22,439 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Shingles
Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)
This study will determine whether ZOSTAVAX™ made with an alternative manufacturing process [ZOSTAVAX™ (AMP)] is well tolerated and immunogenic, and has a comparable immune response to ZOSTAVAX™.
- Trial name
- NCT01505647
- Testing
- Zoster Vaccine, Live (AMP), Zoster Vaccine, Live
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Shingles
ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)
This study will evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ in Korean adults. Approximately 180 herpes zoster history negative subjects ≥ 50 years of age will be enrolled in the study.
- Trial name
- NCT01556451
- Testing
- Zoster Vaccine Live
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Shingles
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).
- Trial name
- NCT00109122
- Testing
- zoster vaccine live (Oka/Merck)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Shingles
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular.
- Trial name
- NCT01331161
- Testing
- ZOSTAVAX
- Where
- 2 sites in United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Emory University
Herpes Zoster, Shingles
A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
The purpose of this study is to compare the safety and efficacy of two doses of FV-100 to valacyclovir in patients with herpes zoster, or shingles.
- Trial name
- NCT00900783
- Testing
- valacyclovir, FV-100
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Neuralgia, Shingles
Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia
The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with painful post-herpetic neuralgia (PHN).
- Conditions
- Neuralgia, Shingles, Peripheral Nervous System Disease
- Trial name
- NCT00099528
- Testing
- REN-1654
- Where
- 16 sites in United States
- Volunteers
- 90 people
- Sponsor
- Renovis
Postherpetic Neuralgia, Shingles
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
This study will evaluate the safety and efficacy of 2 weeks of topical KD7040 versus placebo in the treatment of postherpetic neuralgia.
- Conditions
- Postherpetic Neuralgia, Shingles, Herpes Zoster, Neuropathic Pain
- Trial name
- NCT00576108
- Testing
- KD7040 Topical Gel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Kalypsys, Inc.
Herpes Zoster, Neuralgia
NGX-4010 for the Treatment of Postherpetic Neuralgia
The purpose of the study is determine if an investigational drug, NGX-4010 (high-concentration capsaicin dermal patches) is effective in treating pain associated with post-herpetic neuralgia (PHN).
- Conditions
- Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases
- Trial name
- NCT00061776
- Testing
- Capsaicin Dermal Patch
- Where
- 28 sites in United States
- Volunteers
- 300 people
- Sponsor
- NeurogesX
Peripheral Nervous System Diseases, Pain
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
The purpose of the study is to assess the efficacy and safety of NGX-4010 applied for 60 minutes for the treatment of postherpetic neuralgia (PHN).
- Conditions
- Peripheral Nervous System Diseases, Pain, Neuralgia, Herpes Zoster
- Trial name
- NCT00115310
- Testing
- NGX-4010
- Volunteers
- 400 people
- Sponsor
- NeurogesX
Peripheral Nervous System Diseases, Pain
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
The purpose of the study is to assess the efficacy and safety of NGX-4010 applied for 60 minutes for the treatment of postherpetic neuralgia (PHN).
- Conditions
- Peripheral Nervous System Diseases, Pain, Neuralgia, Herpes Zoster
- Trial name
- NCT00300222
- Testing
- NGX-4010
- Volunteers
- 400 people
- Sponsor
- NeurogesX